SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call at 06.30 pm IST on November 01, 2023 for financial results for the second quarter ending September 30, 2023. Sun Pharma announces results for Nidlegy in melanoma treatment
The study assessed neoadjuvant intratumoral Nidlegy (Daromun), followed by surgery, comparing it to surgery alone SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
As per the intimation attached. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2023 ,inter alia, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2023. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate attached. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
CEQUA showed sustained improvement in dry eye disease patients switched from Restasis. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As per the attached letter. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
As per the attached letter. Sun Pharma, Aurobindo recall drugs from US market
The US health regulator stated that Aurobindo Pharma is recalling 9,890 bottles of Rasagiline Tablets, a medication indicated for the treatment of Parkinson's disease, from the US SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma announces US FDA filing acceptance of New Drug Application for Deuruxolitinib